Novo Nordisk reported that ziltivekimab failed to reduce major cardiovascular events in the Phase 3 ZEUS trial, despite lowering inflammation through IL-6 inhibition. The Denmark-based company tested the drug in more than 6,300 patients with cardiovascular disease, chronic kidney disease
